@cbtadvisors
What a day for the most heavily shorted names in SMID-cap biopharma following the $MRNA news and price action today.
Hard not to think we saw some meaningful short covering / forced de-grossing across specialist books, with crowded shorts getting squeezed almost indiscriminately. Some pretty remarkable moves across the group.
$TWST $NTLA $CAPR $HIMS $BEAM $SRPT $CRSPView quoted post on X
$MRK outsized move on Ph3 topline for results in melanoma highlight investor recognition Merck is pivoting from an LOE to a long-term, durable growth story.revisit core MRK thesis, pipeline outlook and peak-sales assumptions across portfolio. upwardly revise our pipeline peak sales +3bn reflecting increased program confidence & see room for upside on 2026-27 catalyst pathView quoted post on X
Not just the biggest $ move in the history of biotech, but also the biggest % move in the history of the S&P500!
By a very wide margin too, and nearly 2 decades since the distant 2nd place had its day in the sun.
Good to see data backing up that this $MRNA move was actually as crazy as it felt!View quoted post on X
ko-fi.com 1969MetsFan just supported Jeff Blankenburg on Ko-fi! ❤️ Ko-fi lets you support creators you love with tips, memberships and shop sales! These early $PMN safety data — 4% total ARIA rate — should get attention today:View quoted post on X
ProMIS preliminary trial results suggest a path to a safer Alzheimer’s treatment statnews.com/2026/07/28/pro…
